Prebiotic UG1601 mitigates constipation-related events in association with gut microbiota: A randomized placebo-controlled intervention study

BACKGROUNDConstipation is a common functional gastrointestinal disorder and its etiology is multifactorial.Growing evidence suggests that intestinal dysbiosis is associated with the development of constipation.Prebiotics are subjected to bacterial fermentation in the gut to produce short-chain fatty acids (SCFAs), which can help relieve constipation symptoms.The prebiotic UG1601 consists of inulin, lactitol, and aloe vera gel, which are known laxatives, but randomized, controlled clinical trials that examine the effects of this supplement on gut microbiota composition are lacking. AIMTo assess the efficacy of the prebiotic UG1601 in suppressing constipation-related adverse events in subjects with mild constipation. METHODSAdults with a stool frequency of less than thrice a week were randomized to receive either prebiotics or a placebo supplement for 4 wk.All participants provided their fecal and blood samples at baseline and at the end of intervention.Gastrointestinal symptoms and stool frequency were evaluated.The concentrations of serum endotoxemia markers and fecal SCFAs were determined.The relative abundance of SCFA-producing bacteria and the gut microbial community in the responders and non-responders in the prebiotics supplementation group were evaluated. RESULTSThere were no significant differences in gastrointestinal symptoms between